Abstract 21P
Background
The malignant progression of bladder cancer is a key influencing factor for its poor prognosis. In recent years, numerous studies have shown that circular RNA (circRNA) can regulate the expression of genes in multi-levels, which may play a key role in malignant tumors.
Methods
This study applied bioinformatics methods to preliminarily screened the differentially expressed circular RNAs between bladder cancer and corresponding adjacent tissue. Real-time quantitative PCR(RT-qPCR) experiments were performed to identify differentially expressed circular RNAs in cell lines and tissues of bladder cancer. The functional experiments including plate cloning, CCK-8, Edu and xenograft tumor models were implemented to investigate the biological behavior changes of bladder cancer induced by knocking down hsa_circ_0009061 in vitro and in vivo. Bioinformatics methods were applied to predict miRNAs that circular RNA might bind to and the miRNA target genes, and the real-time quantitative PCR, RNA pulldown,dual luciferase reporter experiment and western blot were utilized to explore the mechanism of hsa_circ_0009061 regulating bladder cancer progression.
Results
The bioinformatics analysis and RT-qPCR find that hsa_circ_0009061 was downregulated in cell lines and tissues of bladder cancer. After successfully knocking down hsa_circ_0009061 in bladder tumor cells, functional experiments including plate cloning, Edu and CCK-8 revealed that silencing hsa_circ_0009061 could promote the malignant proliferation of bladder tumor cell lines in vitro. Xenograft tumor modelalso verified that silencing hsa_circ_0009061 could promote tumor formation in vivo. Mechanistic studies have shown that hsa_circ_0009061 can act as a competitive endogenous RNA to bind to hsa-miR-889-3p and regulate the expression of CPEB3, resulting in the malignant progression of bladder cancer.
Conclusions
This study found that hsa_circ_0009061 was downregulated in cell lines and tumor specimens of bladder cancer and could affect the progression of bladder cancer. Mechanistically, hsa_circ_0009061 can bind to hsa-miR-889-3p to regulate the expression of CPEB3, suggesting that hsa_circ_0009061 may be a new treatment option for bladder cancer.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
125P - Combination of navitoclax with alpelisib and trametinib to synergistically impair cell viability in high-grade ovarian cancer
Presenter: Lisa Wozelka-Oltjan
Session: Cocktail & Poster Display session
Resources:
Abstract
126P - Effect of sequential antitumoral treatment with immune checkpoint blockade and tyrosine kinase inhibitors in hepatocellular carcinoma
Presenter: Vincenza Ciaramella
Session: Cocktail & Poster Display session
Resources:
Abstract
127P - Novel bone-targeting of activatable sirolimus for targeted therapy of bone-resident cancers
Presenter: Alistare Sadra
Session: Cocktail & Poster Display session
Resources:
Abstract
128P - Network medicine approach identifies small molecule drugs as immune checkpoint inhibitors repurposable for rectal cancer
Presenter: Faheem Ahmed
Session: Cocktail & Poster Display session
Resources:
Abstract
129P - Repurposing existing therapies for adrenal cancer: Unlocking new possibilities
Presenter: Anupama Samantasinghar
Session: Cocktail & Poster Display session
Resources:
Abstract
130P - Restoration of the mutant p53 protein upon treatment with small molecule modulators
Presenter: Elvina Gilyazova
Session: Cocktail & Poster Display session
Resources:
Abstract
131P - Trop 2 and its overexpression in metastatic colorectal cancer patients (mCRCp): Biological, clinical and therapeutic implications
Presenter: Andrea Mancuso Petricca
Session: Cocktail & Poster Display session
Resources:
Abstract
132P - Novel small molecule modulators for activation of mutant tumor suppressor p53
Presenter: Damir Davletshin
Session: Cocktail & Poster Display session
Resources:
Abstract
133P - Cytotoxic efficacy of artificial vesicles obtained from CAR-T cells by ultrasonication
Presenter: Ekaterina Zmievskaya
Session: Cocktail & Poster Display session
Resources:
Abstract
134P - Doxorubicin and olaparib (OLA) synergism in high-grade serous ovarian (HGOC) and triple-negative breast cancer (TNBC) cell lines with olaparib-resistance
Presenter: Jose Alejandro Perez Fidalgo
Session: Cocktail & Poster Display session
Resources:
Abstract